Expression of K2P5.1 potassium channels on CD4+ T lymphocytes correlates with disease activity in rheumatoid arthritis patients

Arthritis Research and Therapy

Volumn 13, Issue 1, 2011, Pages

  Bittner, Stefan ^a   Bobak, Nicole ^b   Feuchtenberger, Martin ^a   Herrmann, Alexander M ^b   Göbel, Kerstin ^b   Kinne, Raimund W ^c   Hansen, Anker J ^d   Budde, Thomas ^b   Kleinschnitz, Christoph ^a   Frey, Oliver ^e   Tony, Hans Peter ^a   Wiendl, Heinz ^b   Meuth, Sven G ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^d NOVO NORDISK A S   (Denmark)

^e JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; POTASSIUM CHANNEL; POTASSIUM CHANNEL K2P5.1; RITUXIMAB; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG; KCNK5 PROTEIN, HUMAN; TANDEM PORE DOMAIN POTASSIUM CHANNEL;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; DISEASE ACTIVITY; DRUG BLOOD LEVEL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; JOINT BIOPSY; MAJOR CLINICAL STUDY; MALE; PARAMETER; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYNOVIAL FLUID; BIOSYNTHESIS; CELL SEPARATION; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ARTHRITIS, RHEUMATOID; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MALE; POTASSIUM CHANNELS, TANDEM PORE DOMAIN; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79952192268     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3245     Document Type: Article

References (14)

1. van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009, 5:531-541. 10.1038/nrrheum.2009.182, 19798027.
2. Feuchtenberger M, Kneitz C, Roll P, Kleinert S, Tony HP. Sustained remission after combination therapy with rituximab and etanercept in two patients with rheumatoid arthritis after tnf failure: case report. Open Rheumatol J 2009, 3:9-13. 10.2174/1874312900903010009, 2684711, 19479056.
3. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998, 41:1845-1850. 10.1002/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K, 9778226.
4. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, Aletaha D, van Riel PL. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis 2009, 68:954-960. 10.1136/ard.2007.084459, 2674547, 18490431.
5. Bittner S, Meuth SG, Gobel K, Melzer N, Herrmann AM, Simon OJ, Weishaupt A, Budde T, Bayliss DA, Bendszus M, Wiendl H. TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system. Brain 2009, 132:2501-2516. 10.1093/brain/awp163, 3031313, 19570851.
6. Meuth SG, Bittner S, Meuth P, Simon OJ, Budde T, Wiendl H. TWIK-related acid-sensitive K+ channel 1 (TASK1) and TASK3 critically influence T lymphocyte effector functions. J Biol Chem 2008, 283:14559-14570. 10.1074/jbc.M800637200, 18375952.
7. Bittner S, Bobak N, Herrmann AM, Göbel K, Meuth P, Höhn KG, Stenner MP, Budde T, Wiendl H, Meuth SG. Upregulation of K2P5.1 potassium channels in multiple sclerosis. Annals of Neurology 2010, 68:58-69. 10.1002/ana.22010, 20582984.
8. Goronzy JJ, Weyand CM. Developments in the scientific understanding of rheumatoid arthritis. Arthritis Res Ther 2009, 11:249.
9. Maxwell L, Singh JA. Abatacept for rheumatoid arthritis. Cochrane Database Syst Rev 2009, (4):CD007277.
10. Dixon W, Massey F. Introduction to Statistical Analysis 1969, New York: McGraw-Hill Companies.
11. Mima T, Nishimoto N. Clinical value of blocking IL-6 receptor. Curr Opin Rheumatol 2009, 21:224-230. 10.1097/BOR.0b013e3283295fec, 19365268.
12. Funahashi K, Koyano S, Miura T, Hagiwara T, Okuda K, Matsubara T. Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level. Mod Rheumatol 2009, 19:507-512. 10.1007/s10165-009-0203-z, 19609487.
13. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, Siri DA, Tomsic M, Alecock E, Woodworth T, Genovese MC. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010, 69:88-96. 10.1136/ard.2008.105197, 19297346.
14. Matsui T, Komiya A, Shimada K, Nakayama H, Tohma S. Neutrophil CD64 as a marker of infection in patients treated with tocilizumab. Mod Rheumatol 2009, 19:696-697. 10.1007/s10165-009-0223-8, 19728012.